Vaccine preparedness--are we ready for the next influenza pandemic?
about
Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin geneA/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.Mitigation approaches to combat the flu pandemic.Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesImmunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccinesConsiderations for the rapid deployment of vaccines against H7N9 influenza.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicConstruction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvantPATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations.Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccineImmunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use.Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains.Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure.
P2860
Q30207890-FE5BBE41-A60F-4CF9-8D49-C63EC6A6056EQ30224538-D8E2FF1A-15CD-4E43-B413-C1503F349D7BQ30226752-7B5CAA1F-80C5-4496-BD34-B0AC6BD8CC82Q30227246-8C8E8B89-D389-4124-9557-B6E1D3823508Q30352121-0545037F-F080-4160-9912-6D9DEE8E2761Q30355688-261DF48A-C567-4821-B0D2-F597D29D7EEDQ30356933-60A42594-663D-40DB-A728-739412F8DA81Q30364635-3DD8D683-6541-4A36-ADCB-96A089706A3BQ30383451-62F24510-FBB7-4562-8E8F-C8F50A843B61Q30387186-D518B0F6-3095-4132-BA19-6F86437D2B12Q30418297-2C096F94-4004-4E62-9264-36C5F6F8A340Q30421549-11B2E879-2D10-4FAC-8A75-A16B04E73233Q34471961-57DDDE54-9BFD-43BE-93AD-FE96B0226697Q34984192-2E9D2FC9-1F5E-4F2F-8A53-76577949090AQ35301495-357790AA-846A-414D-AC48-36368A8E41FDQ36327122-8ADC9527-254D-4BCE-87BA-0DAD645A3993Q36573064-4A9BEA03-AB6C-4F10-8704-0FCE0B4C6A6DQ38056159-F3A1B3A9-B301-4F80-B891-69B9FA3801F5Q40534076-E3FAD51C-4BE3-475F-B4AD-B0A93ADD9E45Q48109162-21C041FF-1013-4611-AC05-C4BBE7D85153
P2860
Vaccine preparedness--are we ready for the next influenza pandemic?
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Vaccine preparedness--are we ready for the next influenza pandemic?
@ast
Vaccine preparedness--are we ready for the next influenza pandemic?
@en
type
label
Vaccine preparedness--are we ready for the next influenza pandemic?
@ast
Vaccine preparedness--are we ready for the next influenza pandemic?
@en
prefLabel
Vaccine preparedness--are we ready for the next influenza pandemic?
@ast
Vaccine preparedness--are we ready for the next influenza pandemic?
@en
P921
P356
P1476
Vaccine preparedness--are we ready for the next influenza pandemic?
@en
P2093
Peter F Wright
P304
P356
10.1056/NEJMP0803650
P407
P577
2008-06-01T00:00:00Z